Nanoparticles for use for treating a neuronal disorder

Inventors

Meyre, Marie-Edith • Pottier, Agnès • Levy, Laurent

Assignees

Nanobiotix SA

Abstract

The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.

Core Innovation

The patent describes nanoparticle and nanoparticle aggregate materials for preventing or treating neurological disorders. The materials include conductor, semiconductor, and insulator classes defined by electrical properties, including dielectric constant ranges and band-gap constraints. The approach targets abnormal neuronal network oscillatory behavior and/or synchronicity by combining nanoparticle administration with subsequent exposure to an electric field.

The core treatment concept comprises administering a nanoparticle or nanoparticle aggregate to a subject and then exposing the nanoparticle or nanoparticle aggregate to an electric field. The disclosed goal is that the subject’s abnormal neuronal network oscillatory behavior and/or synchronicity is at least partially rescued by the treatment. Dependent implementations include exposing the subject or delivering the electric field via electrical or magnetic stimulation modalities.

The description further identifies neuromodulation concepts related to neuronal oscillatory behavior, coherence, and focality/depth of stimulation. Multiple neurological disorder targets are discussed, including Parkinson’s disease model and Alzheimer’s disease model contexts. In vitro experimental examples are described using microelectrode arrays to show that nanoparticle pretreatment can prevent or rescue functional network effects under electrical stimulation.

Claims Coverage

The independent claims each contain a common inventive structure centered on using specified nanoparticle or nanoparticle aggregate materials and exposing the subject or the nanoparticles to an electric field to rescue abnormal neuronal network oscillatory behavior and/or synchronicity. Across the independent claims, there are three main inventive feature groupings: administration of specified conductor/semiconductor/insulator nanoparticle or aggregate materials, exposure to an electric field for rescue, and kit/composition structure requirements.

Across the independent claims, the inventive coverage is directed to methods and kits that use explicitly defined conductor, semiconductor, and insulator nanoparticle or nanoparticle aggregate materials and that rely on exposure to an electric field to at least partially rescue abnormal neuronal network oscillatory behavior and/or synchronicity, with claim-dependent narrowing through the use of a pharmaceutically acceptable support or by requiring at least two distinct nanoparticle or aggregate types.

Stated Advantages

Documented Applications